|
Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.
|
 |
|
This bet comes amid the strong industry buzz around the approval of Revolution Medicines’ OS-doubling pancreatic cancer treatment, Rasonque.
|
|
|
The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan.
|
|
|
Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.
|
|
|
Novo has meanwhile been busy bolstering its pipeline amid a target to launch more than five multi-blockbusters by 2030.
|
|
